Editorial Board ::: Current Biotechnology

ISSN: 2211-551X (Online)
ISSN: 2211-5501 (Print)


Volume 6, 4 Issues, 2017


Download PDF Flyer




Current Biotechnology

This journal supports open access

Aims & ScopeAbstracted/Indexed in


Submit Abstracts Online Submit Manuscripts Online

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Editorial Board

Co-Editor-in-Chief:

Pabulo Henrique Rampelotto (Biography
Pabulo Henrique Rampelotto

Pabulo Henrique Rampelotto is a molecular biologist currently developing his research at the Federal University of Rio Grande do Sul (Brazil). He is Editor-in-Chief of Current Biotechnology and the book series Grand Challenges in Biology and Biotechnology (Springer). He also serves as Associate Editor, Guest Editor and member of the Editorial Board of several scientific journals in the field of Life Sciences and Biotechnology. In his editorial books and special issues, some of the most distinguished team leaders in the field have published their work, ideas and findings, including Nobel Laureates and several of the highly cited scientists according to the ISI Institute.

)

Center of Biotechnology and PPGBCM Federal University of Rio Grande do Sul
Porto Alegre
RS
Brazil



Associate Editors:

Michael W. W. Adams (Biography
Michael W. W. Adams

Dr. Michael W.W. Adams obtained his Ph.D. degree (1979) in Biochemistry from King's College, University of London, UK. He has been employed at University of Georgia, Athens, GA, USA, since 1987, and is currently working there as Georgia Power Professor of Biotechnology and Co-Director, Center for Metalloenzyme Studies. He, as an author/co-author, has been involved in the publication of more than 355 articles in various journals. His national honors involve the following: (1) Elected Member of the American Academy of Microbiology (2003), and (2) Charles Thom Award, Society of Industrial Microbiology (2010).

)

Distinguished Professor
University of Georgia
Athens, GA
USA

Thomas M.S. Chang (Biography
Thomas M.S. Chang

Professor Thomas Ming Swi Chang, O.C., M.D., C.M., Ph.D., FRCP(C), FRS(C), has been called the “Father of Artificial Cells”. As a student of B.Sc. honours at McGill University, he invented and prepared the first artificial cell (Chang, Hon B.Sc. research report, 1957). He continued this research in medical school and then obtained his Ph.D. (on artificial cells including blood substitutes) from the Departments of Chemistry & Physiology, McGill University. Since 1979, he is Director of Artificial Cells and Organs Research Centre at McGill University. He has now published more than 546 full papers and 29 books, and has since developed artificial cell into a very large area around the world.

)

Director
Artificial Cells & Organs Research Centre / Emeritus Professor, Faculty of Medicine, McGill University
Quebec
Canada

Ben Lugtenberg (Biography
Ben Lugtenberg

Dr Ben J J Lugtenberg graduated in Chemistry from Utrecht University and received his PhD in 1971. His studies included (i) mechanisms of action of antibiotics, (ii) structure and biogenesis of bacterial outer membranes, (iii) nodulation and nitrogen fixation by Rhizobium, (iv) plant growth promotion and biocontrol of plant diseases, and (v) bacterial and fungal endophytes. According to the Web of Science he has 238 primary publications, was cited by others over 15,000 times and has a Hirsch index of 70.

)

Emeritus Professor
Leiden University
Leiden
Netherlands

Yasuhisa Asano (Biography
Yasuhisa Asano

Professor Yasuhisa Asano earned his Ph.D. degree (1982) in Applied Microbiology from Kyoto University, Japan. Prof. Asano currently serves as the Director in the Biotechnology Research Center of Toyama Prefectural University. His current research is broadly in the fields of Applied Microbiology, Biochemistry, Molecular Enzymology, and Organic Chemistry. He has also been a pioneer in the development of microscale assays for amino acids and their analogs, and in particular, his rapid and microscale detection of phenylketonuria in newborns is now used routinely in Japan. Prof. Asano has over 220 publications and has 90 patents.

)

Director
Biotechnology Research Center, Toyama Prefectural University
Toyama
Japan

Paul C. Engel (Biography
Paul C. Engel

Paul Engel graduated in Biochemistry at Oxford (1965). A D. Phil. on enzyme kinetics (Oxford, 1968) followed by 2 years studying flavoproteins with Vincent Massey (University of Michigan). On staff of University of Sheffield 1970-1994. Founding Director of Sheffield’s Krebs Institute. Two-year secondment to manage UK Biotechnology Directorate’s ‘Protein Engineering Club’ (late 1980s). From 1994 Professor of Biochemistry at University College Dublin. Research on various enzymes, mainly dehydrogenases, exploring mechanism, genetic errors, protein engineering, biocatalysis etc. Author of Enzyme Kinetics, the Steady-state Approach (1977, 1981) and Pain-free Biochemistry (2009).

)

Emeritus Professor
University College Dublin
Dublin
Ireland

Charles E. Wyman (Biography
Charles E. Wyman

Dr. Charles Wyman leads advancement of cellulosic biomass conversion to sugars and other precursors for biological or catalytic conversion to fuels and chemicals. He is Ford Motor Company Chair in Environmental Engineering and Distinguished Professor in Chemical and Environmental Engineering at the University of California, Riverside. Prior positions include Queneau Distinguished Professor at Dartmouth College and Director of the Biotechnology Center as well as previous positions at the National Renewable Energy Laboratory. Dr. Wyman is founder of Vertimass to commercialize simple ethanol conversion to fungible fuels and was cofounder of Mascoma Corporation. He is a AIChE and AAAS Fellow.

)

Distinguished Professor
University of California
California, CA
USA

Francis J. Castellino (Biography
Francis J. Castellino

Professor Francis J. Castellino obtained his Ph.D. degree (1968) in Biochemistry from University of Iowa, USA. He currently holds the following positions: (1) Kleiderer/Pezold Professor of Biochemistry, University of Notre Dame (1983-present); (2) Director, WM Keck Center for Transgene Research, University of Notre Dame (1996-present); and (3) Adjunct Professor of Biochemistry & Molecular Biology, Indiana University School of Medicine (2006-present). The research interests of Prof. Castellino’s laboratory involve the structure, function and activation of proteins that participate in blood coagulation and blood clot dissolution. He, as an author/co-author, has published more than 450 articles in various journals, having a very noteworthy number of total citations, i.e. around 13,690.

)

Dean Emeritus
College of Science, University of Notre Dame
Notre Dame, IN
USA

Jean-Marie Frère (Biography
Jean-Marie Frère

Jean-Marie Frère obtained a PhD from the University of Montréal (1969) and, after a one-year post-doctoral position at MIT (Cambridge, Mass, USA), an "Agrégation de l'Enseignement supérieur" from the University of Liège in 1976.

From the beginning, he has worked in the field of enzymology and, after 1970, mainly devoted his attention to the mode of action of beta-lactams and to the enzymes involved in the sensitivity or resistance of bateria to this family of antibiotics, i.e. DD-peptidases (or Penicillin binding proteins) and beta-lactamases.

)

Emeritus Professor
University of Liège
Liège
Belgium


Editorial Board Members:

Ralf Anken (Biography
Ralf Anken

Dr. Ralf Anken obtained his Ph.D. degree (1995) in Zoology (Neurobiology) from University of Hohenheim, Germany. In Mar 2008, he joined as Scientific Employee at German Aerospace Center, Institute of Aerospace Medicine, Division Biomedical Research, Cologne, Germany, and since 2010, he is Head of the Division. He has authored/co-authored more than 75 articles in various journals, having total citations of over 670. Dr. Anken’s academic and professional honors include the following: (1) Promotion to “ausserplanmaessiger Professor” (2008), and (2) Science Award of the Universitaetsbund Universitaet Hohenheim e.V. in appreciation of the habilitation treatise (1999).

)

German Aerospace Center
Cologne
Germany

Dominique Bonnet (Biography
Dominique Bonnet

Dr. Dominique Bonnet obtained her Ph.D. degree (1993) with Dr. Martine Guigon and Prof. Albert Najman from University of Paris VII, France. Since 2006, she is Senior Group Leader, Research Scientist, Head of Haematopoietic Stem Cell Laboratory at Cancer Research UK London Research Institute, UK. Dr. Bonnet is leading a large project to tackle acute myeloid leukaemia (AML) – a type of blood cancer. They are trying to understand exactly how AML develops in the bone marrow, the part of the body that produces blood cells. She, as an author/co-author, has published more than 165 articles in various journals, having a significant number of total citations, i.e. around 12,890.

)

Cancer Research UK
London
UK

Wilfred Chen (Biography
Wilfred Chen

Professor Wilfred Chen joined the University of Delaware in January 1, 2011 as the Gore Professor of Chemical Engineering. He obtained his B.S. degree from UCLA in 1988 and his Ph.D. from Caltech in 1993, both in Chemical Engineering. After one-year postdoc in Switzerland, he joined UC Riverside in 1994. He was Professor of Chemical and Environmental Engineering and the holder of Presidential Chair until 2010. His research interests are in Synthetic Biology and Protein Engineering. Prof. Chen has published more than 220 journal papers and delivered over 70 invited lectures. He serves on the editorial board for seven scientific publications including Applied and Environmental Microbiology and Biotechnology and Bioengineering. He is a fellow of the American Association for the Advancement of Science (AAAS) and the American Institute for Medical and Biological Engineering (AIMBE).

Prof. Chen has also received several awards, including NSF Career Award, AIChE Food, Pharmaceutical, and Bioengineering Division 15c Plenary Lecture, Biotechnology Progress Award for Excellence in Biological Engineering Publication, and Daniel I.C. Wang Award for Excellence in Biochemical Engineering.

)

University of Delaware
Newark, DE
USA

Dongsheng Duan (Biography
Dongsheng Duan

Dr. Dongsheng Duan obtained his Ph.D. degree (1997) from University of Pennsylvania, USA. Dr. Duan is Margaret Proctor Mulligan Professor in Medical Research (Molecular Microbiology and Immunology, Neurology, Bioengineering, and Biomedical Sciences) in the School of Medicine at University of Missouri, USA. His research interests involve Recombinant adeno-associated virus (rAAV) transduction biology, Duchenne muscular dystrophy (DMD) gene therapy, Duchenne cardiomyopathy, Canine model of muscular dystrophy, and Free radical in muscle function and aging. Furthermore, his areas of expertise include Virology and Molecular Therapies, Gene Therapy, Neuromuscular biology, and Virology. He, as an author/co-author, has published more than 125 articles in various journals, having total number of citations of around 5,085.

)

University of Missouri
Columbia, MO
USA

Michael Hust (Biography
Michael Hust

Michael Hust studied biology at the Carl von Ossietzky Universität in Oldenburg, Germany, from 1993-1999. He received his PhD from the Leibniz Universität in Hannover, Germany, in 2002. Since end of 2002 he is working as group leader at the Technische Universität Braunschweig, Germany. In 2011, he finished his professorial dissertation (Habilitation) and was appointed as Privatdozent (PD). In 2014 he was appointed as professor for biotechnology.

He published more than 100 articles (including book chapters and reviews) on antibody engineering and phage display. He is working on the development of human and human-like antibodies for proteome research, diagnostics and therapy with a focus on pathogens and toxins. Another field of interest is the identification of biomarkers of pathogens using phage display. He co-founded two biotech companies, the mAb-Factory GmbH in 2007 and the YUMAB GmbH (www.yumab.com) in 2012.

)

Braunschweig University of Technology
Braunschweig
Germany

Alexander M.Seifalian (Biography
Alexander M.Seifalian

Alexander M. Seifalian (AMS) is director of Nanotechnology & Regenerative Medicine Commercialisation at the London BioScience Innovation Centre and Professor of Nanotechnology and Regenerative Medicine. He is Fellow of the Institute of Nanotechnology (FIoN) and Society of Biology (FSB), and has published over 650 peer-reviewed articles, two books and 12 international patents. AMS has a significant track record with regard to generating impact through the translation of technology from the laboratory directly to the clinic and has demonstrated that nanocomposite materials and stem cells are core to the next generation of surgical implants with highly successful outcomes in a number of pioneering projects. This led to the development of the world’s first synthetic trachea, nasal and ear reconstruction, lacrimal duct conduit, and small diameter bypass grafts for coronary artery and vascular replacement, which has entered clinical trials, all of which have been used as first-in-man.

)

University College London
London
UK

Shawn Mansfield (Biography
Shawn Mansfield

Professor Shawn Denton Mansfield obtained his Ph.D. degree (1997) in Forest Products Biotechnology from University of British Columbia, Vancouver, Canada. Since Jul 2009, he holds the positions of Professor and Canada Research Chair in the Department of Wood Science at University of British Columbia. The long-term objective of Prof. Mansfield’s research program is directed at understanding the innate differences in fibre composition and morphological characteristics existing in tree lines within species, and elucidating what impacts these phenotypic traits have on wood processing and product quality. He, as an author/co-author, has published more than 200 articles in various journals, having a significant number of total citations, i.e. around 7,640.

)

University of British Columbia
Vancouver, BC
Canada

Damiano Gustavo Mita (Biography
Damiano Gustavo Mita

Graduated in Physics on December 1969, started his scientific career on 1970 as Researcher of CNR becoming successively Director of Research. Since 1991 Prof. Mita has become full professor of Biophysics at the Second University of Naples. His main research activity is focused on the application of the technology of immobilized enzymes in agro-food and pharmaceutical industry, and in the field of ecotoxicology, particularly on the effects of endocrine disruptors in living organisms. Prof. Mita authored 130 papers, several chapters and some patents.

Actually Prof. Mita is Director of the National Laboratory on Endocrine Disruptors of the Interuniversity Consortium INBB .

)

Institute of Genetics and Biophysics - CNR via Pietro Castellino
Naples
Italy

Girdhar K. Pandey (Biography
Girdhar K. Pandey

Prof. Pandey received Ph.D. from Jawaharlal Nehru University (JNU), India and pursed his post-doctoral research work at the Department of Plant and Microbial Biology, University of California at Berkeley. Currently, he is working as Professor in the Department of Plant Molecular Biology, Delhi University South Campus. His group’s research interest is to understand the detail mechanistic interplay of signal transduction networks in plants under mineral nutrient deficiency and abiotic stresses. He has published more than 60 scientific publications, edited 7 books/volumes and also has 2 US patents.

Visit his lab web-page for further information about research work: http://www.dpmb.ac.in/index.php?page=girdhar-pandey; https://sites.google.com/site/gkplab/home

)

University of Delhi South Campus
New Delhi
India

Arthur J. Ragauskas (Biography
Arthur J. Ragauskas

Arthur Ragauskas held the first Fulbright Chair in Alternative Energy and is a Fellow of American Association for the Advancement of Science, the International Academy of Wood Science and TAPPI. In 2014, he assumed a Governor’s Chair for Biorefining based in University of Tennessee’s Department of Chemical and Biomolecular Engineering, with a complementary appointment in the UT Institute of Agriculture’s Department of Forestry, Wildlife, and Fisheries and serves in the US Energy and Environmental Sciences Directorate, Biosciences Division, at ORNL. His research program is directed at understanding and exploiting innovative sustainable bioresources for biofuels, and bio-based materials and chemicals.

)

University of Tennessee
Knoxville, TN
USA

Peer Schenk (Biography
Peer Schenk

Professor Peer Schenk graduated from Georg August University in Göttingen and completed his PhD at the Max-Planck Institute for Plant Breeding in Cologne. He heads a large research team at The University of Queensland, Australia where he is finding game-changing solutions from Science and Technology to address Food and Energy Security (www.schenklab.com). His work includes the development of new disease resistant plants and algae for food, feed and biofuel, leading to >180 papers and 7 patents. He developed new commercial crop cultivars, constructed the first Algae Energy Farm in Australia and founded start-up companies Nexgen Plants and Qponics Pty Ltd.

)

The University of Queensland
Brisbane
Australia

Alison Smith
University of Cambridge
Cambridge
UK

Tomohiro Tamura (Biography
Tomohiro Tamura

Dr. Tomohiro Tamura did both his B.Sc. and M.Sc. (Major: Nutrition / Sports Sciences) from University of Tsukuba in 1987 and 1989. Later he obtained his Ph.D. degree (Majoring in Molecular Biology) from University of Tokushima in 1993. Since 2014, Dr. Tamura has been a director of Bioproduction Research Institute, National Institute of Advanced Industrial Science and Technology (AIST). Dr. Tamura has also been a Professor in Laboratory of Molecular Environmental Microbiology, Graduate School of Agriculture, Hokkaido University since 2002 . He has around 130 publications in original peer-reviewed articles and 13 in review articles or book chapters.

)

National Institute of Advanced Industrial Science and Technology
Sapporo
Japan

Shang-Tian Yang (Biography
Shang-Tian Yang

Dr. Shang-Tian Yang obtained his Ph.D. degree from Purdue University in 1984. He was awarded Outstanding Contribution Award from Chinese Academic and Professional Association in 1992. His research areas include Biotechnology, Bioengineering, and Bioprocessing. His current research program covers two important areas in bioprocessing and bioengineering. The first one is animal cell culture and tissue engineering; the second one is bioprocessing for value-added products. He has published 280 general articles and 24 patents.

)

The Ohio State University
Columbus, OH
USA

Willem JH van Berkel (Biography
Willem JH van Berkel

Dr. Willem J.H. van Berkel holds personal chair of Molecular Enzymology in the Laboratory of Biochemistry at Wageningen University & Research, the Netherlands. He has made major contributions in the biochemistry, biocatalysis and chemical biology of (redox) enzymes. His expertise is in the following: Bionanotechnology, Biochemistry, Biotechnology, Oxidoreductases, Biocatalysis, Enzymatic cross-linking, Enzymes, Chemical biology, Molecular conformation, Phenolic compounds, Gene discovery, Protein engineering, Protein purification, Proteins, and Proteomics. He, as an author/co-author, has published more than 225 articles in various journals, having a significant number of total citations, i.e. around 6,800.

)

Wageningen University
Wageningen
The Netherlands

Rainer Borriss (Biography
Rainer Borriss

Prof. Rainer Borriss was graduated from Martin-Luther-Universität Halle/Saale with diploma 1971, promotion to Dr. rer. nat. (PhD, 1972) and habilitation to Dr. sc./Dr. habil. (1979). In 1993 he was awarded as Professor for Bacterial Genetics at Humboldt-University Berlin and from 2010 on as scientific director of ABiTEP GmbH Berlin. He has obtained the national award (“Nationalpreis”) for his efforts to establish a process for production of industrial enzymes by GMOs.Prof. Borriss has published more than 70 original papers in leading international journals, more than 15 reviews and book contributions, and has filed 17 patent applications.

)

Humboldt University
Berlin
Germany

Stephen Dalton (Biography
Stephen Dalton

Prof. Stephen Dalton is Professor and GRA Eminent Scholar of Molecular Cell Biology in the Department of Cellular Biology (Coverdell Center) at University of Georgia, USA. His research can be broken down into two broad areas, i.e. the basic understanding of developmental processes and how stem cells can be used for therapeutic purposes. His areas of research include Cells and Disease, and Cells in Development. He, as an author/co-author, has published more than 85 articles in various journals, having a significant number of total citations, i.e. around 5,840.

)

University of Georgia
Athens, GA
USA

Alessandro Giuliani (Biography
Alessandro Giuliani

Alessandro Giuliani took his Laurea in Biological Sciences at Universita' di Roma "La Sapienza" score 110/110 cum laude (Anno Accademico 81/82) with a specialization in Statistics.. He serves as Senior Scientist at Environment and Health Dept. Istituto Superiore di Sanità, Roma,Italy (1997- ). He is Professor (on contract basis) at Pontifical Urbaniana University, Rome. Dr. Alessandro Giuliani is involved since more than thirty years in the generation and testing of soft physical and statistical models for life sciences. He puts a a special emphasis on the elucidation of mesoscopic complex systems like protein sequence/structure prediction, complex network approaches, QSAR, Systems Biology. He contributed (together with Prof. Zbilut and Prof. Webber) to the development of Recurrence Quantification Analysis (RQA) data analysis technique. He is the author of 278 publications on peer-review journals with an H-index = 38.

)

Istituto Superiore di Sanitá
Rome
Italy

Vinod Labhasetwar (Biography
Vinod Labhasetwar

Dr. Vinod Labhasetwar, Ph.D., is currently a Professor of Biomedical Engineering and Director of Cleveland Clinic’s Cancer Nanomedicine program. His laboratory’s primary research focus over the past 25+ years has been in both basic and translational nanomedicine, with specific interest in cancer imaging and therapy (metastasis, drug resistance), cardiovascular diseases (restenosis, cardiac arrhythmia), and neuroprotective treatments for CNS injuries (stroke, spinal cord and blast-associated traumatic brain injury). He has published over 160 peer-reviewed articles and book chapters, editorials, and has given over 100 invited talks. Moreover, Dr. Labhasetwar has over 20 US and International patents.

)

Cleveland Clinic Lerner College of Medicine
Cleveland, OH
USA

Peter X. Ma (Biography
Peter X. Ma

Dr. Peter X Ma received his B.S. in Polymer Chemistry and M.S. in Polymer Materials from Tsinghua University (Beijing, China), and Ph.D. in Polymer Science and Engineering from Rutgers University. He then did his postdoctoral research at MIT and Harvard Medical School on Biomaterials and Tissue Engineering. In 1996, he joined the faculty of the University of Michigan. He is a tenured Full Professor with quadruple appointments in the Department of Biologic and Materials Sciences in the School of Dentistry, the Departments of Biomedical Engineering, Materials Science and Engineering, and the Macromolecular Science and Engineering in the College of Engineering. He has published around 230 journal articles and book chapters along with 4 books to his credit.

)

University of Michigan
Ann Arbor, MI
USA

Argyrios Margaritis (Biography
Argyrios Margaritis

Dr. A. Margaritis, did B.A.Sc. in Chemical Engineering from University of Waterloo, Canada. He did M.S. in Chemical Engineering (Food Eng.) from University of California, Berkeley, U.S.A. Later he did Ph.D. in Biochemical Engineering from University of California, Berkeley, U.S.A. Professor Margaritis's research interests are Biochemical and Biomedical Engineering, Bio-Environmental Engineering, Biofuels (ethanol, butanol and hydrogen gas), Biopolymers, Bioprocess Design, Controlled Release of Pharmaceuticals from Nanoparticles, Fermentation, Fluidized Bioreactors, Supercritical CO2 Extraction of Biopharmaceuticals and Nutraceuticals. Currently, he is a faculty member (professor of chemical engineering) of Armour College of Engineering. Dr. Margaritis has around 205 refereed journal publications and 10 patents to his credit.

)

University of Western Ontario
London, ON
Canada

Ryuichi Morishita (Biography
Ryuichi Morishita

Ryuichi Morishita, M.D., Ph.D., graduated Osaka University Medical School in 1987, and received Ph. D. from Osaka University in 1991. After postdoctoral Fellow at Stanford University School of Medicine, he served as an Assistant Professor, Department of Geriatric Medicine, Osaka University Medical School from 1994 to 1998. Then, from 1998 to 2003, he was Associate Professor, Division of Gene Therapy Science, Osaka University Medical School. Then, he became Professor & Chairman of Division of Clinical Gene Therapy, Graduate School of Medicine, Osaka University Medical School from 2003.

)

Osaka University
Osaka
Japan

Kun Ping Lu (Biography
Kun Ping Lu

Kun Ping Lu, MD, PhD, is a Professor of Medicine at Harvard Medical School and the Chief of the Division of Translational Therapeutics at Beth Israel Deaconess Medical Center. He discovers a unique phosphorylation-specific proline isomerase, Pin1 that helps protect against Alzheimer’s disease and whose aberrant activation helps promote the development of cancer. Based on these discoveries, his laboratory is working to develop an antibody therapy for the early diagnosis and treatment of Alzheimer’s and traumatic brain injury, and Pin1 chemical inhibitors to overcome drug resistance in cancer treatments.

)

Harvard Medical School
Boston, MA
USA

Daniel Rittschof (Biography
Daniel Rittschof

Dr. Daniel Rittschof obtained Ph.D. degree (1975) and M.S. degree from University of Michigan (1970). He was awarded Community Choice Award, Langmuir in 2011 and also awarded Quarterly Journal of Ship Hull Performance in 2011. His areas of focus are: 1) Ecology and behavioral biology of local macroinvertebrates such as blue crabs and mud snails; 2) Barnacle models as they relate to fouling and the prevention of fouling and bioadhesives; 3. Impacts of xenobiotics on behavior and reproduction.

)

Duke University Marine Laboratory
Beaufort, NC
USA

Dmitry Shayakhmetov (Biography
Dmitry Shayakhmetov

Dr. Dmitry Shayakhmetov obtained his B.S. degree in biochemistry and Ph.D. degree in molecular biology and virology under the supervision of one of the leading virologists in Russia, Professor Thomas Tikchonenko. He obtained his postdoctoral training in virology and immunology in the laboratory of Dr. Andre Lieber, at the University of Washington, in Seattle, where he was appointed to faculty as an Assistant Professor (2005) and later promoted to an Associate Professor (2010). In 2008, he was also awarded the Outstanding New Investigator Award by the American Society of Gene and Cell Therapy.

)

University of Washington
Seattle, WA
USA

Tore Straume (Biography
Tore Straume

Dr. Straume received a Ph.D. degree in Biophysics from the University of California in 1982, BS and MS from the University of Washington (1973, 1976). Dr. Straume’s present position at NASA includes advancing our understanding of health effects from radiation exposure during deep space exploration missions such as Mars and the development of methods and technologies to mitigate such hazards. His core expertise is radiation science applied to radiobiology, biophysics, and novel radiation detection technologies. He has also pioneered the development of biotechnologies and is inventor or co-inventor of ten patents in the biotechnology field.

)

NASA Ames Research Center
Moffett Field, CA
USA

Nicholas J. Turner (Biography
Nicholas J. Turner

Dr. Nicholas J. Turner obtained B.Sc. Hons degree in Chemistry from University of Bristol (1979‐1982), and D.Phil. from University of Oxford (1982‐1985). During 1998‐2004 he was Professor of Chemical Biology, University of Edinburgh. Since 2004, he has been a Professor of Chemical Biology in School of Chemistry, University of Manchester. Over the years, Dr. Turner has received numerous awards for his contribution to science.

)

Manchester Institute of Biotechnology, University of Manchester
Manchester
UK

Su-Chun Zhang (Biography
Su-Chun Zhang

Dr. Su-Chun Zhang obtained M.D. from the Wenzhou Medical College, Wenzhou, and Ph.D. from the University of Saskatchewan, Canada. Until recently, Zhang was Professor of Anatomy and Neurology and a research group leader at the University of Wisconsin–Madison. In January 2005, Zhang's group differentiated human blastocyst stem cells into neural stem cells, then further into the starts of motor neurons, and eventually into spinal motor neuron cells (which play important role in delivering information from the brain to the spinal cord in the human body).

)

University of Wisconsin
Madison, WI
USA

Ben Berkhout (Biography
Ben Berkhout

Dr. Ben Berkhout, Ph.D., was appointed as professor of Human Retrovirology at the Faculty of Medicine of the University of Amsterdam (UvA) on Sep 1, 2002. Dr. Berkhout studies the HIV-1 virus and AIDS, the development of a vaccine and a new antiviral therapy. The Berkhout research group received twice the AIDS Research Amsterdam award: in 1997 for a contribution to the 'EMBO Journal', and in 1999 for a contribution to the 'Journal of Virology'. He, as an author/co-author, has published more than 510 articles in various journals, having a very significant number of total citations, i.e. around 18,575.

)

University of Amsterdam
Amsterdam
The Netherlands

Bruce A. Bunnell (Biography
Bruce A. Bunnell

Dr. Bruce Alan Bunnell obtained his Ph.D. degree (1990) in microbiology (molecular genetics) from University of Alabama at Birmingham, Alabama, USA. He holds the following key positions: (1) Chair, Division of Gene Therapy, Tulane National Primate Research Center, Tulane University, New Orleans, LA, USA (2002 to present); (2) Director, Center for Stem Cell Research and Regenerative Medicine, Tulane University (2009 to present); and (3) Gratis Faculty, Pennington Biomedical Research Center, Baton Rouge, LA, USA (2008 to present). He, as an author/co-author, has published more than 135 articles in various journals (having total number of citations of around 7,120), over 13 book chapters, and 2 books.

)

Tulane University Health Sciences Center
Covington, LA
USA

Nikolay V. Dokholyan (Biography
Nikolay V. Dokholyan

Dr. Nikolay V. Dokholyan obtained his Ph.D. degree (1999) in Physics from Boston University, USA. Since 2009, he is Director in the Center for Computational and Systems Biology at University of North Carolina at Chapel Hill, USA. Dr. Dokholyan is Founder and President of the Molecules in Action, LLC (2008 to present). His research focus is in the areas of Computation/Experimental biophysics and structural biology. His laboratory focuses on understanding etiologies of human diseases, such as cystic fibrosis (CF), amyotrophic lateral sclerosis (ALS), and conditions, such as hyperalgesia. He, as an author/co-author, has published more than 240 articles in various journals, having a significant number of total citations, i.e. around 8,335.

)

University of North Carolina
Chapel Hill, NC
USA

José M. Guisan (Biography
José M. Guisan

Dr. José Manuel Guisan obtained his Ph.D. degree (1979) in Biochemistry from University Autonoma of Madrid, Spain. Dr. Guisan is currently a full Professor at Spanish Research Council (CSIC) since 2001 and a Visiting Professor at St. Bartholomew’s Hospital Medical School. All his research activity has focused on the implementation of enzymes as industrial catalysts. That is, in the development of strategies that allow to overcome the limitations of enzymes (instability, low activity towards non-natural substrates, difficulty of purification, etc.) to be able to use their excellent catalytic properties. He, as an author/co-author, has published more than 400 articles in various journals, having a significant number of total citations, i.e. around 16,250.

)

Instituto de Catalisis CSIC
Madrid
Spain

Yuehe Lin (Biography
Yuehe Lin

Dr. Yuehe Lin is a professor in School of Mechanical and Materials Engineering, Washington State University (WSU). He also holds a joint appointment at Pacific Northwest National Laboratory (PNNL), conducts research in nanotechnology, particularly development of small-scale devices, materials and analytical systems for biomedical diagnosis, drug delivery and energy and environmental applications. He has ~400 publications with a total citation about 33,000 and h-index 95. He was listed in Thomson Reuters’s highly-cited researchers in 2014, 2015 and 2016. Dr. Lin has over 10 patents. Half of the patents have been licensed to industrial partners for commercialization. He is a fellow of AAAS, Royal Society of Chemistry, and American Institute of Medical and Biological Engineering.

)

Washington State University
Pullman, WA
USA

Datta Madamwar (Biography
Datta Madamwar

Dr. Datta Madamwar obtained his M.Sc. in Microbiology from Nagpur University, Nagpur, and Ph.D. from Birla Institute of Technology and Science, Pilani, India. Since Jun 1998, he is Professor in the Department of Biosciences at Sardar Patel University, Vallabh Vidyanagar. His major work involves molecular phylogenetic approaches (based on 16S rDNA amplification, RFLP, ARDRA, DGGE, TGGE, etc.) to determine Uncultivable and Cultivable bacterial diversity of heavy metal resistant bacteria and polycyclic aromatic compounds degrading organisms. He, as an author/co-author, has published more than 200 articles in various journals, having total number of citations of around 4,715.

)

Sardar Patel University
Vallabh Vidyanagar
India

Nicolas Mermod (Biography
Nicolas Mermod

Dr. Nicolas Mermod, Diplôme (equivalent to M.Sc.) in Biochemistry, with Prof. J.-P.Giacobino, Dept. of Medical Biochemistry, University of Geneva (1981-1982). He did Doctorat ès Sciences (Ph.D. Thesis), with Prof. K.N. Timmis, Dept of Medical Biochemistry, University of Geneva (1982-1986). Later he did Postdoctoral training in the group of Prof. R. Tjian, Dept. of Biochemistry, University of California, Berkeley, USA (1986-1989). Since 2001, he is Co-founder and board member of a Biotechnology company, Selexis SA, Switzerland. Currently, he is also Director of the Institute of Biotechnology, Faculty of Biology and Medicine, University of Lausanne. Dr. Mermod has numerous publications to his credit.

)

Director of Institute of Biotechnology
Lausanne
Switzerland

Poonam Singh Nigam (Biography
Poonam Singh Nigam

Dr Poonam Singh (Nigam), PhD in Industrial Microbiology (1985), Postdoctoral Research Fellow Germany (1985-1988), joined Ulster University, UK as full time staff in 1990. Qualified as Chartered Biologist (1992), received Post-graduate qualification in University Teaching, UK (1998), the status of Fellow and Senior Fellow - The Higher Education Academy, UK in 2007 and 2014, respectively; Fellow of Royal society of Biology, London UK, Fellow - Centre of Higher Education Research & Practice, UK 2014, Fellow - International Forum on Industrial Bioprocesses, France 2014, Fellow - The Biotechnology Research Society India (2013). Google Scholar http://scholar.google.co.uk/citations?user=-Pkpe_cAAAAJ&hl=en

)

University of Ulster
Coleraine
UK

Guy M. Poppy (Biography
Guy M. Poppy

Dr. Guy M. Poppy, did DPhil University of Oxford (1987- 1990). He did BSc, ARCS Imperial College of Science Technology and Medicine (1984-1987). He was appointed as Visiting Professor – Imperial College (2010). Since 2011, he is Professor and Director of Interdisciplinary Research and Director of University Strategic Research Groups (reporting to PVC Research). He is responsible for coordinating multidisciplinary strategy at the University of Southampton and Leading 11 Grand Challenge cross-faculty groupings securing about £100 million of research income and central to the University Vision and Strategy.

)

University of Southampton
Hampshire
UK

Badal C. Saha (Biography
Badal C. Saha

Dr. Badal Saha obtained his Ph.D. in Microbial Technology from Kyushu University, Japan. He is working as Research Chemist at USDA-ARS, Peoria, IL. Dr. Saha has over 32 years of research experience in fermentation and industrial biotechnology. He has authored 181 research publications (including book chapters and review articles), 198 meeting abstracts and 9 patents. He is currently Editor-in-Chief of Fermentation (open access journal). Dr. Saha has served as President of the Society for Industrial Microbiology and Biotechnology (2010-11). He is a Fellow of the American Academy of Microbiology and Society for Industrial Microbiology and Biotechnology.

)

National Center for Agricultural Utilization Research
Peoria, IL
USA

Ashok Shetty (Biography
Ashok Shetty

Dr. Ashok K. Shetty, obtained his B.Sc. degree in Zoology, Chemistry and Botany, Mysore University, Mysore, India (1980). He did M.Sc. in Human Anatomy, Mysore University, Mysore, India (1983). Later, he became Ph.D. in Neuroscience, All India Institute of Medical Sciences, New Delhi, India (1990). Since 1991, Dr. Shetty is a Medical Research Scientist, Medical Research Service, Veterans Administration Medical Center, Durham, North Carolina. Currently he is also a Professor in Department of Surgery, Division of Neurosurgery, Duke University Medical Center, Durham, North Carolina. His peer reviewed publications include 89 research articles, 71 original research articles and 18 review articles.

)

Duke University Medical Centre
Durham, NC
USA

Jeffrey P. Sutton (Biography
Jeffrey P. Sutton

Dr. Jeffrey Paul Sutton did his undergraduate studies in Mathematics and Physics, subsequently earning his M.D., M.Sc. and Ph.D. (Theoretical Physics) degrees from the University of Toronto. He completed his postgraduate medical education at Harvard Medical School. He is the Friedkin Professor and Founding Director of the Center for Space Medicine at Baylor College of Medicine, and also the Chairman of the Board of the NASA-supported Translational Research Institute for Space Health. He is the former Chief Executive Officer of the National Space Biomedical Research Institute.

)

President, CEO and Institute Director, National Space Biomedical Research Institute
Houston, TX
USA

Jeremy S. Webb (Biography
Jeremy S. Webb

Jeremy S. Webb obtained his Ph.D. degree in Microbiology from University of Manchester, UK in 2000. He was the Director of the Graduate School of Biological Sciences at University of Southampton, UK (2012-2016) and become Professor of Microbiology at University of Southampton, UK (2015-Present). He has published 59 journal articles, 3 book chapters and has filed 2 patents.

)

University of Southampton
Southampton
UK

Ruiwen Zhang (Biography
Ruiwen Zhang

Dr. Zhang has extensive expertise and experiences in translational biomedical research, particularly translational medicine, cancer therapy and prevention, pharmacogenomics and therapeutics. He has published more than 210 papers, 2 books, more than 50 invited reviews/book chapters, and more than 180 meeting abstracts. Dr. Zhang has made more than 200 invited presentations. He is a certified toxicologist by the American Board of Toxicology (D.A.B.T.). He is also an editor-in-chief, associate-editor-in-chief, associate editor, or editorial board member of 25 scientific journals. Dr. Zhang has been elected as a Fellow of American Association for the Advancement of Science (AAAS) since 2009.

)

Texas Tech University Health Sciences Center
Amarillo, TX
USA


Editorial Board Members: (Biotechnology Industry)

Malaz Abutarif (Biography
Malaz Abutarif

Dr. Malaz Abutarif obtained his B.Sc. degree in pharmacy from Jordan University of Science and Technology (1992 – 1997) and Ph.D. in Pharmaceutical Sciences- Pharmacokinetics from LIU Brooklyn (1997 – 2002). Later he also did MBA in Program and Project Management from Keller Graduate School of Management (2003 – 2006). Since 2013, he has been associated with Bristol-Myers Squibb as Group Director.

)

Director
Bristol-Myers Squibb
Princeton, NJ
USA

David Boulton (Biography
David Boulton

Dr. David Boulton has broad experience in Clinical Pharmacology/Pharmacokinetics aspects of drug development focused on the Metabolic Diseases, Cardiovascular Diseases, Fibrosis, Virology, and Neuroscience therapeutic areas as an individual contributor and in a leadership role. Also he has wide-ranging experience in regulatory document preparation (briefing books, NDA and sNDA Biopharmaceutics and Clinical Pharmacology Summaries), active participant in FDA Advisory Committee meetings, face-to-face and teleconference meetings with regulators and in preparing responses to Health Authority written questions. Currently, he is accountable for Quantitative Clinical Pharmacology aspects for AZ's late-phase diabetes assets.

)

Executive Director, AstraZeneca
Gaithersburg, MD
USA

Nancy B. Griffith (Biography
Nancy B. Griffith

Dr. Nancy B. Griffith obtained her Ph.D. degree in Experimental Psychology from Temple University (1989 – 1994). She has worked in Biogen Idec as Senior Director, Medical Communications and Training and now currently as a Vice President, Medical Excellence and Operations. Previously Dr. Griffith worked in Scientific Connexions as Senior Director, Medical Communications.

)

Vice President, Biogen Idec
Boston, MA
USA

Manfred Kircher (Biography
Manfred Kircher

Based on more than 30 years’ experience in chemical industry and bioeconomy he works on regional as well as international bioeconomy strategies. Manfred Kircher’s career milestones are biotechnological research and development (Degussa AG, Germany), production (Fermas s.r.o.; Slovakia), venture capital (Burrill & Company; USA), biotechnology partnering and branding (Evonik Industries AG; Germany) and building the bioeconomy cluster CLIB2021 (Germany). In 2014 he joined KADIB, a company consulting on important aspects of industrial bioeconomy.

)

Chairman of the Advisory Board, Cluster Industrielle Biotechnologie - CLIB2021
Düsseldorf
Germany

Tarek Leil (Biography
Tarek Leil

Dr. Tarek Leil obtained Ph.D. in Pharmacology from University of California, Los Angeles (1997 – 2004) and M.S. in Biotechnology (2005 – 2007). Currently, he is Group Director (Head of Quantitative Clinical Pharmacology) at Bristol-Myers Squibb. Dr. Leil is basically a drug development scientist with a specialization in clinical pharmacology and pharmacometrics and experience in drug development for cardiovascular diseases, metabolic diseases, neuroscience, and oncology. He has experienced in leading both functional area and multi-disciplinary R&D matrix teams. Also Dr. Leil has experience in a variety of regulatory interactions to facilitate different phases of clinical development.

)

Director, Bristol-Myers Squibb
Princeton, NJ
USA

Faisal Mehmud (Biography
Faisal Mehmud

Dr. Faisal Mehmud is currently a Vice President, US Oncology Clinical Development & Medical Affairs, at Novartis, East Hanover, New Jersey, USA (Mar 2015 to Present). Prior to joining Novartis, he worked at GlaxoSmithKline (GSK) on the positions of Head of North American Medical Affairs (Oncology), Global Medical Director and European Medical Director (spanning from Apr 2008 to Mar 2015). He also worked at Sanofi / Sanofi-Aventis, from Jan 2003 to Apr 2008, on the positions of Global Medical Director (in Paris Area, France) and Medical Advisor (Oncology; in London, UK).

)

Vice President
Novartis
East Hanover, NJ
USA

John J. Renger (Biography
John J. Renger

John leads the clinical research group within Purdue Pharma, Stamford, CT. Prior to joining Purdue, Dr. Renger spent 15 years with Merck where he was a key innovator for Belsomra, a first-in-class dual orexin receptor antagonist for primary insomnia. John was a Merck-MIT Fellow at the Massachusetts Institute of Technology, where his work focused on understanding the genetic, developmental and physiological basis of memory. Before MIT, Dr. Renger worked at the Institute for Chemical and Physical Research, RIKEN, Japan studying the genetic basis of plasticity in the visual system. Dr. Renger earned his B.S. and Ph.D. degrees in biology from the University of Iowa.

)

Associate Vice President
Merck
West Point, PA
USA

Bernardo Silva (Biography
Bernardo Silva

Dr. Bernardo Silva is an Economist and International Affairs professional with experience of over a decade, of global corporate and government affairs, in Latin America, North America and Europe, and has an extensive network of top-level government authorities, international organizations’ officials, and senior executives from the world’s leading corporations. He is currently Executive President at Brazilian Industrial Biotechnology Association (ABBI), Brazil (Jan 2015 to Present). His specialties include International Business Development; Strategic Advice; Partnerships and Community Building; Global Corporate and Government Affairs; Foreign Direct Investments and Trade Promotion; Policy Analysis and Advocacy.

)

Executive President
Brazilian Industrial Biotechnology Association (ABBI)
São Paulo
Brazil

Michael Wagner (Biography
Michael Wagner

Dr. Michael Wagner is currently Director, Head of Peptides, R&TM Diabetes Division, at Sanofi, Frankfurt, Germany (Oct 2012 to Present). He is also Director Medicinal Chemistry / Head of Medicinal Chemistry 3 - R&D Diabetes Division, at Sanofi-Aventis (Apr 2010 to Present). Previously he worked on the following positions at Sanofi: (1) Senior Principal Scientist, Sanofi-Aventis (Jan 2006 to Apr 2010); and (2) Research Scientist, Sanofi-Aventis (Feb 2002 to Dec 2005). This shows that he has been committed to working at Sanofi and has contributed to a large extent in terms of success at this company.

)

Director and Head
Sanofi
Frankfurt
Germany

Khursheed Anwer (Biography
Khursheed Anwer

Dr. Khursheed Anwer, Ph.D., M.B.A., has been the Chief Scientific Officer and Executive Vice President at Celsion Corporation since 2014. Before joining Celsion, he served as President and Chief Scientific Officer of Expression Genetics, Inc. (formerly, EGEN) from June 2009 to June 2014 and its Vice President of Research and Development from July 2002 to June 2009. He Joined Expression Genetics in July 2002. Before joining EGEN, he served as Director of Pre-Clinical Development at Valentis, Inc. from July 2000 to June 2002. He served as a member of the board of directors of EGEN from 2010 to 2014.

)

President and Chief Scientific Officer, EGEN
Huntsville, AL
USA

Seng H. Cheng (Biography
Seng H. Cheng

Dr. Seng Hing Cheng obtained his B.Sc. degree (First Class with Honors in Biochemistry) and Ph.D. degree in Biochemistry from the Department of Biochemistry, University of London, U.K during the period of 1976-1983. Since 2011, he has been the Global Head of Research, Rare Diseases at Sanofi. Dr. Cheng has earned several awards for his contributions over the years. Dr. Cheng has published around 250 Research Articles and 20 Book Chapters and also has over 100 issued patents to his credit.

)

Vice President
Genzyme Corporation
Framingham, MA
USA

Rafiq Hasan (Biography
Rafiq Hasan

Dr. Rafiq Hasan obtained MBBS (Medicine) degree during 1986 – 1992 from University of London, United Medical and Dental Schools and St Thomas' Hospital Medical School. Dr. Hasan trained as a physician in United Kingdom. After 3 years in clinical practice, he entered the pharmaceutical industry. During the period of 18 years, he gained vast experience in a variety of commercial and clinical roles of responsibility both in the United Kingdom and at international level at Novartis and Bayer. Before joining Bayer (in his present role in 2013), Dr. Hasan was the Global Head of Ophthalmology at Novartis Pharma AG.

)

Vice President and Global Head
Bayer HealthCare
Newbury
UK

Alexandra Kropotova (Biography
Alexandra Kropotova

Dr. Kropotova received her M.D. from Vladivostok State Medical School and MBA from Ohio University. She has 15+ years of successful track record of executive bio-pharmaceutical experience in Global R&D, Medical Affairs, Global Strategy, Global portfolio development and innovations. She has worked at major bio-pharmaceutical companies such as Pfizer, Wyeth, Sanofi, and Genzyme. Her work experience includes major strategic and leadership positions in leading portfolio design and development of compounds through the full drug development value chain. She is experienced in leading clinical development of multiple drug modalities including but not limited to small molecules, biologics, therapeutic vaccines and drugs.

)

Vice President and Head
Sanofi
Bridgewater, NJ
USA

Stacy R. Lindborg (Biography
Stacy R. Lindborg

Dr. Stacy R. Lindborg, Ph.D., is a Vice President, Biostatistics, Biogen Idec, where she has been working since 2012. Prior to this, she was at Eli Lilly & Company for 16 years spanning a number of roles, including Sr. Dir., Global Statistics & Advanced Analytics, Director R&D Strategy & Decision Sciences, etc. Dr. Lindborg’s research interests include applications of novel design and analysis methods to solve real world problems in the pharmaceutical industry. Specific areas of interest include Bayesian methodology, Adaptive Designs, Missing Data problems, and Portfolio Productivity. She has 35+ collaborative and methodological manuscripts published in various journals, having a significant number of total citations, i.e. around 2,580 (Scopus accessed on 10-Nov-2017).

)

Vice President, Biostatistics, Biogen Idec
Cambridge, MD
USA

Jose Ricardo Perez (Biography
Jose Ricardo Perez

Dr. Jose Ricardo Perez, M.D., has a background in oncology, with 15 years of experience in pharmaceutical multinational companies as a medical adviser and 17 years as a medical practitioner. The specialties of Dr. Perez include the following: competitive analysis, consulting, customer relations, design, focus, latin, macromedia director, market planning, marketing, protocols, research, safety, sales, scientific, strategic, strategic planning, and vision. He is currently a Senior Medical Director, US CPO Solid Tumors, at Novartis, East Hanover, New Jersey, USA (Nov 2013 to present).

)

Senior Medical Director
Novartis
East Hanover, NJ
USA

Alison Schecter (Biography
Alison Schecter

Dr. Alison Schecter, M.D., completed her Internal Medicine residency at the Johns Hopkins Hospital and her Cardiology fellowship at Massachusetts General Hospital with a research fellowship at Mount Sinai. She is currently a Vice President of Cardiovascular and Metabolism (CVM) Scientific Innovation at the J&J Innovation Center, Boston. In her role at J&J, Dr. Schecter is responsible for identifying novel product opportunities and technologies, leading cross-functional teams, both internally and externally, and jointly developing deal structures. In a global health role, her NIH-supported academic research focused on chemokine and cytokine signaling in cardiovascular and viral diseases with over 50 peer-reviewed papers.

)

Vice President, Johnson & Johnson Innovation Center
Boston, MA
USA

Paul-Peter Tak (Biography
Paul-Peter Tak

Paul-Peter Tak received his medical degree cum laude from the Free University in Amsterdam and was trained as an internist, rheumatologist and immunologist at Leiden University Medical Center, where he also received his PhD. He served as Professor of Medicine and Chair of the Department of Clinical Immunology and Rheumatology at the Academic Medical Centre/University of Amsterdam (AMC) for 12 years. He is currently Chief Immunology Officer and Senior Vice President R&D Pipeline at GSK. He has published extensively in peer-reviewed scientific journals and is a Fellow of the Academy of Medical Sciences.

)

Senior Vice President, GlaxoSmithKline
Stevenage
UK

Scott Wasserman (Biography
Scott Wasserman

Dr. Wasserman received his M.D., Magna Cum Laude from Harvard Medical School and his B.S., Magna Cum Laude from Haverford College. He completed his postgraduate training in Internal Medicine and Cardiovascular Medicine at Stanford University.

Currently, Dr. Wasserman is the Vice President, Head of the Cardiovascular and Metabolic Therapeutic Area and Head of the Development Design Center at Amgen. He is responsible for Amgen’s cardiovascular and metabolic strategy through the development and registration of novel cardiovascular and metabolic therapeutics, evaluating and in-licensing external assets, and optimizing and innovating the design of clinical development programs and studies across Amgen.

)

Vice President
Amgen
Thousand Oaks, CA
USA

Alex Berlin (Biography
Alex Berlin

Dr. Alex Berlin’s past 20 years of professional biotech career, he applied his abilities to innovate as a scientist, process developer, manager, or an entrepreneur. This led him through a non-linear evolution of his path across continents, different cultures, and languages. Specifically, he has worked on multiple projects in industrial biotechnology, including: design and development of plant biomass bio refinery processes for production of liquid biofuels and biochemical, industrial enzymes process and product development, and novel lignin-based chemicals and materials. Currently, he is R&D Director Biotechnology Research, Head Protein Chemistry and Site Management Leadership Member at Novozymes and also Expert Panel Member for Sustainable Energy Systems at NSERC.

)

R&D Director Biotechnology Research, Novozymes
Davis, CA
USA

Neil J. Clarke (Biography
Neil J. Clarke

Dr. Neil J. Clarke is highly motivated and successful scientific leader with extensive experience of leading and supporting drug discovery programmes (small molecule and biopharmaceuticals) across many stages of drug discovery. He is experienced in line & matrix management of groups and programmes across multiple UK sites and also transnationally. Extensive experience of setting up, managing and directing multi-partner collaborative research programmes, with external (academic and biotech) groups and in scientific ‘due diligence’ activities across the business. He is excellent communicator with a long history of publication in the scientific literature and in presenting to the external scientific community. Also he is a scientific opinion leader with experience of influencing at the highest levels within research organizations.

)

Director & Head of Molecular Profiling, GlaxoSmithKline
Stevenage
UK

William Kennedy (Biography
William Kennedy

Dr. William Kennedy’s received training academic experience is in the areas of structural biology, molecular genetics, protein chemistry, nucleic acid chemistry, developmental biology, pediatrics and infectious diseases. He is a pediatric infectious disease specialist in San Francisco, California. He received his medical degree from Stanford University School of Medicine and has been in practice for more than 20 years. He is currently Senior Medical Director at Genentech (September 2012 – Present). His professional goals include regenerative medicine, biotech innovation in novel drug platforms, novel biomarkers, translational medicine, infectious disease, autoimmunity, neurobiology and pediatric drug development.

)

Senior Medical Director
Genentech
South San Francisco, CA
USA

Jesper Lau (Biography
Jesper Lau

Dr. Jesper Lau studied biology and chemistry at the University of Southern Denmark. After his Ph.D. in organic chemistry in 1990, and a research visitor stay in the group of Professor Barry Trost at Stanford University in California, he joined Health Care Discovery at Novo Nordisk. Jesper Lau possesses long-term expertise within combinatorial chemistry, medicinal chemistry and drug discovery, but since 2002, has been engaged in protein and peptide engineering. The main focus has been establishing technologies to improve the therapeutic properties of endogenous peptides and proteins.

)

Vice President
Novo Nordisk
Copenhagen
Denmark

Michael Linden (Biography
Michael Linden

Michael Linden is currently working as a Vice President of Gene Therapy at Pfizer, London, UK (since Dec 2014). He is also working as Professor of Virology at King's College London (since Aug 2007). Previously, he has worked on the following positions: (1) Director, Gene Therapy Consortium, UCL Cancer Institute, University College London (Jan 2012 to Sep 2015); (2) Associate Professor, Mount Sinai School of Medicine (1997 to 2007); (3) Postdoctoral fellow, Cornell University (1990 to 1996).

)

Vice President, Gene Therapy, Pfizer
London
UK

T. Shantha Raju (Biography
T. Shantha Raju

Dr. Raju obtained a doctorate (Ph.D.) in Chemistry from the University of Mysore, Mysore, INDIA. Dr. Raju also holds a Masters in Chemistry from the University of Mysore. Currently Dr. Raju is a Senior Director and Head of Global Bioassay & Quality at Medimmune. He has published more than 40 scientific publications including several book chapters and is named inventor of several issued U.S and worldwide patents. Dr. Raju is currently serving as the Editorial Board member of several journals.

)

Scientific Director, Janssen, Pharmaceutical Companies of Johnson and Johnson
Springhouse, PA
USA

Rob Scott (Biography
Rob Scott

Dr. Rob Scott is an internationally mobile physician with 27 years of experience in executive leadership positions in the Global Pharmaceutical Industry. He has a broad range of experience across the entire spectrum of drug discovery and development, strategic lifecycle planning and medical affairs. He currently holds the following positions: (1) Vice President Global Development, Head Amgen Development Design Center, at Amgen (Oct 2014 to Present); and (2) Head of Global Cardiovascular, Metabolic & Neuroscience Development, at Amgen (Nov 2010 to Present). He designed and developed the first approved "PolyPill" (a single tablet to treat more than one disease), Caduet.

)

Vice President and Head
Amgen
Los Angeles, CA
USA

Michael Teufel (Biography
Michael Teufel

Dr. Michael Teufel did his Masters (1987) in Biology from the University of Kiel, Germany, obtained his Ph.D. (1992) in Molecular Genetics from University of Göttingen, Germany, and then completed his Post-Doc (1994) in Molecular Pharmacology at Marion Merrell Dow Research Institute. He is currently Director Biomarker Strategy Oncology at Bayer HealthCare (Jul 2012 to Present). He has been involved in the following activities at Bayer HealthCare: Biomarker Project Lead for early and late stage projects; Implementation of translational concepts from bench to bedside; Support of biomarker results for regulatory drug approval; Focus on Clinical Development in POC Studies; CDx development; and Drug Development in Asia.

)

Director
Bayer HealthCare
New York, NY
USA

Dennis M. Zaller (Biography
Dennis M. Zaller

Dr. Dennis M. Zaller completed his B.S. (1979) in Biology from University at Albany (SUNY), New York, USA. Dr. Zaller then obtained his Ph.D. (1987) in Biological Sciences from Columbia University in the City of New York. He is currently Executive Director at Celgene (Oct 2015 to Present), where he focuses on Alliance Research, Immunology & Inflammation. Previously, he has worked on the following positions: (1) Executive Director, Merck (Sep 1990 to Sep 2015), and (2) Senior Research Fellow, California Institute of Technology (Sep 1987 to Aug 1990).

)

Executive Director, Celgene
Boston, MA
USA












Advertisement
3D Cell Culture

Related Journals




Related eBooks



Webmaster Contact: info@benthamscience.org Copyright © 2017 Bentham Science